Navigating U.S. Trade Controls and Compliance Challenges in the Life Sciences Sector in China

Eric Carlson participated in this in-depth webinar on the critical U.S. trade controls and related compliance issues facing the life sciences sector in China. The timely discussion provided actionable insights to help organization's manage evolving risks and strengthen compliance frameworks. The program covered:

• Export Controls Risks: Identifying and mitigating risks associated with dual-use controls on certain biotechnology items, as well as end-user and end-use restrictions, including Military End Use and End User (MEU) controls (e.g., military-affiliated hospitals) and Entity List controls (e.g., clinical trials at or sales to hospitals affiliated with Entity List universities).
• Sanctions Risks: Identifying and mitigating risks associated with supplying to, sourcing from, or partnering with sanctioned parties (e.g., sanctioned parties in Xinjiang and volume-based procurement (VBP) implications).
• Countermeasures: Navigating emerging Chinese countermeasures (e.g., Unreliable Entities List and Countering Foreign Sanctions Law) and PRC trade controls.
• Bulk Sensitive Data Controls: Considerations and best practices for managing controls on U.S. sensitive personal data in cross-border operations.
• What’s on the Horizon: Key trends and potential regulatory changes, including the BIOSECURE Act and possible expansion of MEU controls.